

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the “Shanghai Junshi Biosciences Co., Ltd.* Announcement on Re-election of the New Session of the Board of Directors and the Board of Supervisors” published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 30 May 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong, Dr. Zou Jianjun, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr. Feng Hui and Mr. Tang Yi as non-executive Directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.

* *For identification purpose only*

Shanghai Junshi Biosciences Co., Ltd.*
Announcement on Re-election of the New Session of
the Board of Directors and the Board of Supervisors

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

Given that the term of the third session of the board of directors (the “**Board**” and the “**Directors**” respectively) and the third session of the board of supervisors (the “**Board of Supervisors**” and the “**Supervisors**” respectively) of Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) will be expiring, in accordance with the laws and regulations such as the Company Law of the People’s Republic of China (《中華人民共和國公司法》) (the “**Company Law**”) and the Rules Governing the Listing of Stocks on the STAR Market of Shanghai Stock Exchange (《上海證券交易所科創板股票上市規則》), and the Articles of Association of Shanghai Junshi Biosciences Co., Ltd.* (the “**Articles of Association**”), the Company held the thirty-second meeting of the third session of the Board and the twenty-third meeting of the third session of the Board of Supervisors on 30 May 2024 at which the resolutions relating to, among other things, the re-election of the new session of the Board and the Board of Supervisors of the Company were considered and approved. The particulars are hereby announced as follows:

I. Re-election of the New Session of the Board

In accordance with the Articles of Association, the fourth session of the Board of the Company shall consist of 14 Directors, including 5 independent non-executive Directors. The Company held the thirty-second meeting of the third session of the Board on 30 May 2024 at which the Resolution on the Nomination of Executive Directors and Non-executive Directors of the Fourth Session of the Board of Directors and the Resolution on the Nomination of Independent Non-executive Directors of the Fourth Session of the Board of Directors were considered and approved. After the examination of the qualifications by the nomination committee under the third session of the Board of the Company, the

Board of the Company agreed to nominate Mr. XIONG JUN, Mr. NING LI, Ms. ZOU JIANJUN, Mr. LI CONG, Mr. ZHANG ZHUOBING, Mr. SHENG YAO, Mr. GANG WANG and Ms. LI XIN as the candidates for executive Directors of the fourth session of the Board of the Company, Mr. TANG YI as the candidate for the non-executive Director of the fourth session of the Board of the Company, and Mr. ZHANG CHUN, Mr. FENG XIAOYUAN, Mr. MENG ANMING, Mr. SHEN JINGKANG and Ms. YANG YUE as the candidates for independent non-executive Directors of the fourth session of the Board of the Company, and Mr. ZHANG CHUN is an accounting professional. For the biographical details of the aforesaid candidates for Directors, please see the appendix.

According to the relevant requirements, the Directors of the fourth session of the Board of the Company will be elected by cumulative voting system at the general meeting of the Company. The term of office of Mr. ZHANG CHUN, a candidate for independent non-executive Directors, shall commence on the date of consideration and approval at the general meeting and expire on the date on which he has served as an independent non-executive Director of the Company for six consecutive years (i.e. 18 June 2026). The term of office of other candidates for Directors shall be three years from the date of consideration and approval at the general meeting. The qualifications and independence of the aforesaid candidates for independent non-executive Directors have been reviewed and approved without objection by the Shanghai Stock Exchange.

II. Re-election of the New Session of the Board of Supervisors

In accordance with the Articles of Association, the fourth session of the Board of Supervisors of the Company shall consist of three Supervisors, including two non-employee representative Supervisors and one employee representative Supervisor. The Company held the twenty-third meeting of the third session of the Board of Supervisors on 30 May 2024 at which the Resolution on the Nomination of Non-employee Representative Supervisors of the Fourth Session of the Board of Supervisors was considered and approved. The Board of Supervisors agreed to nominate Ms. KUANG HONGYAN and Ms. WANG PINGPING as the candidates for non-employee representative Supervisors of the fourth session of the Board of Supervisors of the Company. For the biographical details of the aforesaid candidates for Supervisors, see the appendix.

The aforesaid two candidates for non-employee representative Supervisors will form the fourth session of the Board of Supervisors of the Company together with the one employee representative supervisor elected at the employee representatives meeting of the Company. The non-employee representative Supervisors of the fourth session of the Board of Supervisors of the Company will be elected by cumulative voting system at the general meeting of the Company. Their term of office shall be three years from the date of consideration and approval at the general meeting.

III. Other Explanations

The qualifications of the aforesaid candidates for Directors and Supervisors are in compliance with the requirements for the qualifications of directors and supervisors under relevant laws, administrative regulations and regulatory documents. In addition, the ratio of candidates for independent non-executive Directors to the candidates for the fourth session of the Board is not less than one-third of the total number of Directors. The candidates for independent non-executive Directors have the educational background and work experience required to fulfill the duties of independent directors, and comply with the relevant requirements regarding the qualifications and independence of independent directors of, among other things, the Measures for the Administration of Independent Directors of Listed Companies (《上市公司獨立董事管理辦法》). In order to ensure the normal operation of the Board, the third session of the Board of the Company shall continue to perform the duties of Directors in accordance with the relevant requirements of the laws and regulations and the Articles of Association before the new session of the Board takes office.

The Company would like to express its sincere gratitude to the Directors of the third session of the Board for their contribution to the development of the Company during their term of office.

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

31 May 2024

** For identification purpose only*

Appendix:

I. Biographical Details of the Candidates for Executive Directors

Mr. XIONG JUN (熊俊), born in February 1974, with Chinese nationality and without the right of permanent residence abroad, obtained his bachelor's degree in economics from Zhongnan University of Economics (now known as Zhongnan University of Economics and Law) in July 1996 and his MBA from the Chinese University of Hong Kong in December 2007. Mr. XIONG JUN has been the chairman of the Board of the Company since March 2015. He served as the general manager of the Company from January 2016 to January 2018. Since February 2007, he has been an executive director of Shanghai Baoying Asset Management Co., Ltd.*. From March 2013 to November 2015 and from September 2013 to November 2015, he served as the chairman and the general manager of Shanghai Union Biopharm Biosciences Co., Ltd.* (“Shanghai Union Biopharm”), respectively. Since April 2013, he has been an executive director, chairman of the board of directors and general manager of various subsidiaries of the Company.

As of the date of this announcement, XIONG FENGXIANG and his son XIONG JUN are the controlling shareholders and de facto controllers of the Company. XIONG FENGXIANG, his son XIONG JUN and their persons acting in concert together hold 217,835,186 shares of the Company (including 217,832,586 A shares and 2,600 H shares), representing 22.10% of the total share capital of the Company. In addition to the above circumstances, Mr. XIONG JUN does not have any related relationship with other shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management. There are no circumstances that would prohibit him from serving as a Director of the Company pursuant to the provisions of the Company Law. There are no circumstances where he is prohibited by the China Securities Regulatory Commission (the “CSRC”) from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where he is publicly identified by a stock exchange to be unsuitable to act as a director of a listed company. Mr. XIONG JUN is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. He complies with the conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

Mr. NING LI (李寧), born in October 1961, with American nationality and the right of

permanent residence in China, has been the vice chairman of the Board of the Company and the chairman of the board of directors of TopAlliance Biosciences Inc (“TopAlliance”), a wholly-owned subsidiary of the Company since January 2024; since June 2018, he has been an executive Director of the Company. From January 2018 to January 2024, he served as the general manager of the Company. Mr. NING LI obtained his bachelor’s degree in medicine from Shanghai First Medical College (上海第一醫學院) in July 1984; he obtained his master’s degree in medicine from Shanghai Medical University (上海醫科大學) in October 1987 and his Ph.D. degree in preventive medicine/biostatistics from University of Iowa, the U.S. in August 1994. From May 1994 to January 1997, Mr. NING LI served as a senior researcher of WESTAT, the research cooperation center of NIH AIDS in the U.S.; from February 1997 to September 2009, he successively served as a reviewer, senior reviewer, team leader of review team, branch director at the U.S. Food and Drug Administration; from September 2009 to January 2018, he successively served as a senior director, assistant to vice president and vice president of the registration and medical policy department of Sanofi Global R&D, Bridgewater, New Jersey; from January 2007 to December 2010, he was a part-time professor at Johns Hopkins University, the U.S.; from November 2010 to November 2012, he was a guest professor at the Clinical Research Institute of Peking University; from January 2012 to December 2014, he was a part-time professor at the Medical Informatics Center of Peking University.

As of the date of this announcement, Mr. NING LI directly holds 50,000 A shares of the Company. Mr. NING LI does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit him from serving as a Director of the Company pursuant to the provisions of the Company Law. There are no circumstances where he is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where he is publicly identified by a stock exchange to be unsuitable to act as a director of a listed company. Mr. NING LI is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People’s Court. He complies with the conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

Ms. ZOU JIANJUN (鄒建軍), born in July 1971, with Chinese nationality and the right of permanent residence in America, has been the general manager and the chief executive officer of the Company since January 2024. From April 2022 to January 2024, she served as a deputy general manager and global research and development president of the Company. Since June 2022, she has been an executive Director of the Company. Ms. ZOU JIANJUN graduated with a bachelor's degree in clinical medicine from the Fourth Military Medical University* (第四軍醫大學) in July 1995. From August 1995 to August 2000, she served as the resident and attending physician at the department of oncology under the department of clinical medicine at the 301 Hospital of the People's Liberation Army* (解放軍 301 醫院); from August 2000 to September 2005, she served as the attending physician at the department of oncology at the Shanghai Changzheng Hospital* (上海長征醫院); she obtained her Ph.D. degree in clinical oncology from the Second Military Medical University* (第二軍醫大學) in August 2005. From October 2005 to October 2012, she served as the medical manager of the research and development department and the head of the oncology therapeutic team of Bayer China, and the head of global medical affairs at the United States headquarters of Bayer Pharmaceuticals in New Jersey. From October 2012 to September 2015, she served as the head of China Medical Affairs at Celgene Pharmaceuticals in the United States. From September 2015 to April 2022, she served as the chief medical officer and deputy general manager at Jiangsu Hengrui Pharmaceutical Co., Ltd.* (江蘇恒瑞醫藥股份有限公司).

As of the date of this announcement, Ms. ZOU JIANJUN has not directly held any shares of the Company. Ms. ZOU JIANJUN does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit her from serving as a Director of the Company pursuant to the provisions of the Company Law. There are no circumstances where she is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where she is publicly identified by a stock exchange to be unsuitable to act as a director of a listed company. Ms. ZOU JIANJUN is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. She complies with the

conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

Mr. LI CONG (李聰), born in April 1964, with Chinese nationality and without the right of permanent residence abroad, has served as an executive Director and the co-chief executive officer of the Company since November 2021. Mr. LI CONG obtained his bachelor's degree in medicine from Shanghai Tiedao University School of Medicine (now known as Tongji University School of Medicine) in July 1986. From July 1986 to December 1997, he was a lecturer on pathological anatomy of Shanghai Tiedao University School of Medicine; from December 1997 to January 2004, he served as the sales director of the Shanghai branch of NOVO Nordisk (China) Pharmaceuticals Co., Ltd.; from January 2004 to March 2019, he served as the manager of East China Region, sales director, assistant to the general manager and general manager at Tonghua Dongbao Pharmaceutical Co., Ltd.; since June 2019, he has been a director and general manager of Suzhou Landing Biopharmaceutical Co., Ltd.* (蘇州蘭鼎生物製藥有限公司). From December 2016 to November 2021, he served as a non-executive Director of the Company.

As of the date of this announcement, Mr. LI CONG directly holds 127,020 A shares of the Company. Mr. LI CONG does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit him from serving as a director of a company pursuant to the provisions of the Company Law. There are no circumstances where he is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where he is publicly identified by a stock exchange to be unsuitable to act as a director of a listed company. Mr. Li CONG is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. He complies with the conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

Mr. ZHANG ZHUOBING (張卓兵), born in May 1967, with Chinese nationality and without the right of permanent residence abroad, has been a deputy general manager of the Company since May 2016; since December 2016, he has been an executive Director of the Company. Mr. ZHANG ZHUOBING obtained his bachelor's degree in biology from Xinjiang

University in July 1988 and his master's degree in biochemistry from Tsinghua University in July 1995. From January 1997 to May 2004, he served as a department manager of Yantai Medgenn Biopharmaceutical Co., Ltd. (煙台麥得津生物醫藥有限公司); from May 2005 to October 2008, he served as a scientific researcher of Viron Therapeutics Inc., Canada; from November 2008 to September 2011, he served as a deputy director in Institute of Biopharmaceuticals of Nanjing Simcere Pharmaceutical Research Institute (南京先聲藥物研究院生物藥物研究所); since February 2011, he has been the chairman of Yongzhuo Boji (永卓博濟); from November 2011 to November 2015, he served as a director and deputy general manager of Shanghai Union Biopharm. He has been an executive director, general manager and legal representative of Suzhou Union since October 2013, an executive director, general manager and legal representative of Wuxi Junshi Biomedical Technology Co., Ltd.* (無錫君實生物醫藥科技有限公司) since December 2022, an executive director and legal representative of Wuxi Runmin Pharmaceutical Technology Co., Ltd.* (無錫潤民醫藥科技有限公司) since December 2022, an executive director and legal representative of Shanghai Junshi Biotechnology Co., Ltd. since August 2023, an executive director, general manager and legal representative of Suzhou Junmeng Biopharm Co., Ltd. * (蘇州君盟生物醫藥科技有限公司) since August 2023, the legal representative of Shanghai Runmin Changjian Biomedical Technology Co., Ltd.* (上海潤民長健生物醫藥技術有限公司) since December 2023.

As of the date of this announcement, Mr. ZHANG ZHUOBING directly holds 40,000 A shares of the Company. Mr. ZHANG ZHUOBING does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit him from serving as a director of a company pursuant to the provisions of the Company Law. There are no circumstances where he is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where he is publicly identified by a stock exchange to be unsuitable to act as a director of a listed company. Mr. ZHANG ZHUOBING is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. He complies with the conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

Mr. SHENG YAO (姚盛), born in October 1975, with American nationality, has served as an executive Director of the Company from March 2015 to May 2015; from June 2014 to August 2020, he served as the senior vice president of TopAlliance; he has been the chief executive officer of TopAlliance since August 2020 and an executive Director and deputy general manager of the Company since December 2016. Mr. SHENG YAO obtained his bachelor's degree in biotechnology from Peking University in June 1998; he obtained his Ph.D. degree in molecular genetics from Albert Einstein College of Medicine, the U.S., in January 2003. From January 2003 to April 2004, he was a postdoctoral researcher at Mayo Medical School; from May 2004 to December 2010, he was one of the faculty member and a research assistant at the Johns Hopkins University School of Medicine; from January 2011 to October 2011, he was a researcher in the School of Medicine at Yale University; from October 2011 to June 2014, he was a senior scientist at Amplimmune Inc., a subsidiary of AstraZeneca.

As of the date of this announcement, Mr. SHENG YAO has not directly held any shares of the Company. Mr. SHENG YAO does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit him from serving as a director of a company pursuant to the provisions of the Company Law. There are no circumstances where he is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where he is publicly identified by a stock exchange to be unsuitable to act as a director of a listed company. Mr. SHENG YAO is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. He complies with the conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

Mr. GANG WANG (王剛), born in July 1957, with American nationality and the right of permanent residence in China, has served as a deputy general manager and chief quality officer of the Company since August 2019, and an executive Director of the Company since October 2023. Mr. GANG WANG obtained his bachelor's degree in biochemistry from basic department of Nanjing University in July 1982; he obtained his master's degree in biochemistry from Suzhou Medical College (蘇州醫學院) in July 1988 and obtained his doctoral degree in pharmacology and toxicology from the School of Medicine of Dartmouth College in the United

States (美國達特茅斯醫學院) in September 1995. From October 1995 to June 1998, Mr. GANG WANG engaged in post-doctoral research at the U.S. National Institutes of Health; from June 1998 to July 1999, he served as a research scientist at Osiris Therapeutics in the United States; from August 1999 to August 2003, he served as a biologist at the research institute of National Institutes of Health in the United States; from August 2003 to June 2005, he served as an assistant professor at the University of Texas, the U.S.; from June 2005 to April 2017, he served as a senior policy advisor, an assistant officer of the China office, a senior reviewer and presiding officer of the U.S. FDA; from April 2017 to April 2018, he was the chief scientist of the Center for Drug Evaluation of CFDA responsible for compliance and inspection; from May 2018 to August 2019, he served as the vice president of Shanghai quality department of Wuxi Biologics (Cayman) Inc. (無錫藥明生物技術股份有限公司); he has been an independent director of Obio Technology (Shanghai) Co., Ltd. since January 2021, an independent director of Shanghai Hengrun Dasheng Biotechnology Co., Ltd.* (上海恆潤達生生物科技股份有限公司) since June 2021, and an independent director of Hangzhou Sciwind Biosciences Co., Ltd.* (杭州先為達生物科技股份有限公司) since September 2023.

As of the date of this announcement, Mr. GANG WANG directly holds 10,000 A shares of the Company. Mr. GANG WANG does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit him from serving as a director of a company pursuant to the provisions of the Company Law. There are no circumstances where he is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where he is publicly identified by a stock exchange to be unsuitable to act as a director of a listed company. Mr. GANG WANG is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. He complies with the conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

Ms. LI XIN (李鑫), born in March 1979, with Chinese nationality and without the right of permanent residence abroad, has served as an executive Director and the Senior Vice President of Government Affairs of the Company since February 2024, and served as a non-executive Director of the Company from October 2023 to February 2024. Ms. LI XIN obtained

a Ph.D. degree in Enterprise Development and Strategic Management from Fudan University in 2005 and obtained an Executive Master of Business Administration (EMBA) degree from the Tsinghua University PBC School of Finance in 2022. From September 2014 to December 2020, Ms. LI XIN served as a vice president of Greenland Financial Holdings Group Co., Ltd.* (綠地金融投資控股集團有限公司). She has served as a vice president of Greenland Jinchuang Technology Group Co., Ltd.* (綠地金創科技集團有限公司) since January 2021; a director of Greenland Digital Technology Co., Ltd.* (綠地數字科技有限公司) since August 2022; and an executive director of Shanghai Jiakai Investment Management Co., Ltd.* (上海加財投資管理有限公司) since April 2015.

As of the date of this announcement, Ms. LI XIN directly holds 53,260 shares of the Company (including 12,060 A shares and 41,200 H shares). Ms. LI XIN serves as an executive director of Shanghai Jiakai Investment Management Co., Ltd. and a director of Greenland Digital Technology Co., Ltd. (Greenland Financial Holdings Group Co., Ltd., Shanghai Jiakai Investment Management Co., Ltd. and Greenland Financial Overseas Investment Group Co., Ltd. are shareholders together directly holding more than 5% of the shares of the Company. Greenland Digital Technology Co., Ltd. holds 100% equity interest of Greenland Financial Holdings Group Co., Ltd.). In addition to the above circumstances, Ms. LI XIN does not have any related relationship with the controlling shareholders, de facto controllers, other Directors, Supervisors and senior management of the Company. There are no circumstances that would prohibit her from serving as a director of a company pursuant to the provisions of the Company Law. There are no circumstances where she is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where she is publicly identified by a stock exchange to be unsuitable to act as a director of a listed company. Ms. LI XIN is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. She complies with the conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

II. Biographical Details of the Candidates for Non-Executive Directors

Mr. TANG YI (湯毅), born in December 1968, with Chinese nationality and the right of permanent residence in New Zealand, has been a non-executive Director of the Company since May 2015. Mr. Tang Yi graduated from Huaqiao University and obtained his bachelor's double

degree in mechanical engineering and business management in January 1990. From 1991 to 1993, Mr. TANG YI served as a department manager of Shenzhen Shekou Foreign Economic Development Company* (深圳蛇口對外經濟發展公司); from 1993 to 1996, he served as the general manager of Shenzhen Yuesi Industrial Co., Ltd* (深圳市粵絲實業公司). Since 1996, he has been the chairman of the board of directors and General Manager of Shenzhen Finevalue Technology Co., Ltd.* (深圳市泛友創業投資有限公司); since April 2013, he has served as a director of Qianhai Yuanben (前海源本); since July 2013, he has been the representative appointed by the executive partner at Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)* (蘇州瑞源盛本生物醫藥管理合夥企業)(有限合夥) (“Ruiyuan Shengben”).

As of the date of this announcement, Mr. TANG YI directly holds 7,774,500 A shares of the Company. Mr. TANG YI has been the representative appointed by the executive partner at Ruiyuan Shengben, a concert party with the de facto controllers of the Company. In addition to the above circumstances, Mr. TANG YI does not have any related relationship with other shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit his from serving as a director of a company pursuant to the provisions of the Company Law. There are no circumstances where he is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where he is publicly identified by a stock exchange to be unsuitable to act as a director of a listed company. Mr. TANG YI is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People’s Court. He complies with the conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

III. Biographical Details of the Candidates for Independent Non-Executive Directors

Mr. ZHANG CHUN (張淳), born in July 1957, with Chinese nationality and without the right of permanent residence abroad, has been an independent non-executive Director of the Company since June 2020. Mr. ZHANG CHUN graduated in accounting from Jiangxi University of Finance and Economics in 1985, and graduated in law from Party School of the Central Committee of C.P.C in 2001. He is qualified as a Chinese Certified Public Accountant and a Senior Accountant. His main experience includes: from August 1978 to July 1992, he

had held various positions in the Industry and Transport Division of the Department of Finance of Jiangsu Province, including the deputy section chief, section chief and deputy division director; from August 1992 to December 1993, he served as the deputy general manager of Jiangsu High and New Technology Venture Capital Company* (江蘇省高新技術風險投資公司); from December 1993 to December 1995, he served as the president of Jiangsu Assets and Equity Exchange and the general manager of Jiangsu Asset Appraisal Company* (江蘇資產評估公司); from December 1995 to December 1999, he served as the director of Jiangsu Certified Public Accountants Company* (江蘇會計師事務所); from December 1999 to September 2010, he served as the director of the asset appraisal center under the Department of Finance of Jiangsu Province; from September 2010 to August 2017, he served as the division chief of Jiangsu Rural Comprehensive Reform Working Group Office; he has been retired since August 2017. He has served as an independent director of Zhejiang Goldensea Hi-Tech Co., Ltd. since August 2023.

Mr. ZHANG CHUN does not directly hold any shares of the Company. He does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit him from serving as a director of a company pursuant to the provisions of the Company Law. There are no circumstances where he is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where he is publicly identified by a stock exchange to be unsuitable to act as a director of a listed company. Mr. ZHANG CHUN is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. He complies with the conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

Mr. FENG XIAOYUAN (馮曉源), born in August 1956, with Chinese nationality and without the right of permanent residence abroad, has served as an independent non-executive Director of the Company since December 2021. Mr. FENG XIAOYUAN obtained his bachelor's degree in medicine from Shanghai First Medical College in 1982 and a doctor's degree in diagnostic radiology Shanghai Medical University in 1988. He worked as an operator of the Shanghai Fifth Pharmaceutical Factory from December 1975 to February 1978. He was a radiologist at Huashan Hospital of Fudan University from December 1982 to November 2016.

He served as the deputy dean and secretary of the Party Committee at Huashan Hospital of Fudan University from April 2000 to May 2008. From May 2007 to June 2011, he served as the dean of Shanghai Medical College of Fudan University. He served as the vice president of Fudan University from May 2011 to July 2015, and since August 2016, he has served as a tenured professor (honorary position, non-faculty position) at Huashan Hospital of Fudan University. He has been appointed as the chairman of the board of directors of Lunqin (Shanghai) Medical Technology Co., Ltd.* (倫琴(上海)醫療科技有限公司) since November 2016. He has served as the dean of Shanghai Penta Innovation & Entrepreneurship Institute since January 2018. He has been the president and legal representative of Shanghai Society of Biomedical Engineering since September 2023.

Mr. FENG XIAOYUAN does not directly hold any shares of the Company. He does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit him from serving as a director of a company pursuant to the provisions of the Company Law. There are no circumstances where he is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where he is publicly identified by a stock exchange to be unsuitable to act as a director of a listed company. Mr. FENG XIAOYUAN is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. He complies with the conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

Mr. MENG ANMING (孟安明), born in July 1963, with Chinese nationality and without the right of permanent residence abroad, has served as an independent non-executive Director of the Company since June 2023. Mr. MENG ANMING received a bachelor's degree in agronomy from Southwest Agricultural University* (西南農業大學) in July 1983, and a doctorate degree in genetics from the University of Nottingham in the United Kingdom in November 1990. He was elected as an academician of the Chinese Academy of Sciences in 2007 and an academician of The World Academy of Sciences for the advancement of science in developing countries in 2008. From December 1990 to December 1992, Mr. MENG ANMING worked as a postdoctoral researcher at the School of Biology, China Agricultural University. From December 1992 to August 1998, he served as an associate professor at the

School of Biology, China Agricultural University, during which from March 1996 to August 1998, he was a visiting scholar at the Institute of Molecular Medicine and Genetics, Medical College of Georgia in the United States. Since August 1998, he has been a professor at the School of Life Sciences, Tsinghua University

Mr. MENG ANMING does not directly hold any shares of the Company. He does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit him from serving as a director of a company pursuant to the provisions of the Company Law. There are no circumstances where he is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where he is publicly identified by a stock exchange to be unsuitable to act as a supervisor of a listed company. Mr. MENG ANMING is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. He complies with the conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

Mr. SHEN JINGKANG (沈競康), born in May 1951, with Chinese nationality and without the right of permanent residence abroad. Mr. SHEN JINGKANG obtained his bachelor's degree in pharmacy from Shanghai First Medical College in August 1975, and obtained his Master of Science degree in Pharmacy from Shanghai Medical University in July 1986. He obtained his doctoral degree in pharmacy from Kyoto University in Japan in September 1993, and engaged in postdoctoral research in pharmacy at Shanghai Institute of Materia Medica, Chinese Academy of Sciences from January 1994 to September 1995. From September 1995 to May 2016, he worked as a researcher and doctoral supervisor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He has served as the chairman of the board of directors of Shanghai Ringene Biopharma Co. Ltd.* (上海凌達生物醫藥有限公司) since September 2018 and an independent director of Yantai MabPlex International Biomedical Co., Ltd. since January 2022.

Mr. SHEN JINGKANG does not directly hold any shares of the Company. He does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit him

from serving as a director of a company pursuant to the provisions of the Company Law. There are no circumstances where he is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where he is publicly identified by a stock exchange to be unsuitable to act as a supervisor of a listed company. Mr. SHEN JINGKANG is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. He complies with the conditions for serving as a director under the relevant laws, regulations and provisions including the Company Law.

Ms. YANG YUE (楊悅), born in March 1973, with Chinese nationality and without the right of permanent residence abroad. Ms. YANG YUE obtained her bachelor's degree in pharmaceutical business management from Shenyang Pharmaceutical University in July 1995, obtained her master's degree in pharmacology from Shenyang Pharmaceutical University in July 1998, and obtained her doctoral degree in pharmacy from Shenyang Pharmaceutical University in July 2004. From August 1998 to November 2011, she served as a lecturer and associate professor at the School of Business Administration of Shenyang Pharmaceutical University. From December 2011 to September 2020, she served as a professor and PhD supervisor. In October 2020, she joined the School of Pharmaceutical Sciences of Tsinghua University as a researcher and doctoral supervisor. She is the leader of the discipline of drug regulatory science of Tsinghua University, the director of the Key Laboratory of Innovative Drug Research and Evaluation of National Medical Products Administration, and a director of China Center for International Economic Exchanges.

Ms. YANG YUE does not directly hold any shares of the Company. She does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit her from serving as a director of a company pursuant to the provisions of the Company Law. There are no circumstances where she is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where she is publicly identified by a stock exchange to be unsuitable to act as a supervisor of a listed company. Ms. YANG YUE is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. She complies with the conditions for serving as a director under the

relevant laws, regulations and provisions including the Company Law.

IV. Biographical Details of the Candidates for Non-employee Representative Supervisors

Ms. KUANG HONGYAN (匡洪燕), was born in November 1971, with Chinese nationality and without the right of permanent residence abroad. Ms. KUANG HONGYAN graduated from Jiangxi University of Finance and Economics with a bachelor's degree in management in 1993 and obtained a master's degree in finance from Nankai University in July 2005. She served as a lecturer at the accounting department of Jiangxi University of Finance and Economics from September 1993 to October 1996, and a staff member of the accounting and settlement department, a deputy general manager of the accounting and settlement department and a deputy general manager of the human resources department of Shenzhen branch, and the vice president, a deputy general manager of the retail business department and the general manager of the service management department of Overseas Chinese Town sub-branch of China Construction Bank. From 2010 to 2019, she served as a deputy general manager of the legal and compliance department and the general manager of the human resources department of the Shanghai branch, China Everbright Bank. Since 2019, she has served as the chairman of Anhui Zhongyi Zhilv Information Technology Co., Ltd. (安徽中意之旅信息科技股份有限公司), an executive director and the general manager of Anhui Zhongyi Credit Limited (安徽中意微信有限公司) and an executive director of Shanghai Zhongyi Zhifu Asset Management Company Limited (上海中意之富資產管理有限公司).

As of the date of this announcement, Ms. KUANG HONGYAN does not directly hold any shares of the Company. Ms. KUANG HONGYAN does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit her from serving as a supervisor of a company pursuant to the provisions of the Company Law. There are no circumstances where she is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where she is publicly identified by a stock exchange to be unsuitable to act as a supervisor of a listed company. Ms. KUANG HONGYAN is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. She complies with the conditions for serving as a supervisor under the relevant laws,

regulations and provisions including the Company Law.

Ms. WANG PINGPING (王萍萍), born in January 1982, with Chinese nationality and without the right of permanent residence abroad, has served as an external Supervisor of the Company since June 2018. Ms. WANG PINGPING obtained a bachelor's degree in statistics from Shanghai University of Finance and Economics in June 2003 and a master's degree in economics from Shanghai University of Finance and Economics in January 2006. Ms. WANG PINGPING has been a full-time teacher at the College of Economics and Management of the Shanghai University of Electric Power since March 2006.

As of the date of this announcement, Ms. WANG PINGPING does not directly hold any shares of the Company. Ms. WANG PINGPING does not have any related relationship with the controlling shareholders, de facto controllers, shareholders holding more than 5% of the shares of the Company, other Directors, Supervisors, and senior management of the Company. There are no circumstances that would prohibit her from serving as a supervisor of a company pursuant to the provisions of the Company Law. There are no circumstances where she is prohibited by the CSRC from access to securities market and the said prohibition has not yet expired, and there are also no circumstances where she is publicly identified by a stock exchange to be unsuitable to act as a supervisor of a listed company. Ms. WANG PINGPING is not punished or disciplined by the CSRC, any stock exchange and other relevant authorities, and is not a dishonest person subject to enforcement action as announced by the Supreme People's Court. She complies with the conditions for serving as a supervisor under the relevant laws, regulations and provisions including the Company Law.